New Releases from NCBI BookshelfIptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].Iptacopan (Fabhalta): Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Fabhalta be reimbursed by public drug plans for the treatment of adult patients with […]
